Results 11 to 20 of about 6,564,767 (266)

Assessment of potential drug interactions among psychiatric inpatients receiving antipsychotic therapy of a secondary care hospital, United Arab Emirates

Journal of Advanced Pharmaceutical Technology & Research, 2021
The majority of the antipsychotic drugs are also known to interact with other co-administered drugs. Drug–drug interaction (DDI) reports among patients receiving antipsychotic medications are common.
Haneen A. R. Aburamadan, Sathvik Belagodu Sridhar, Talaat Matar Tadross   +2 more
doaj   +1 more source

Drug-drug interactions in the hospital [PDF]

, 2007
Introduction Drug interaction screening programs are an important tool to check prescriptions of multiple drugs for potential drug-drug interactions (pDDIs). Several programs are available on the market.
Vonbach, Priska
core   +1 more source

Alternative Methotrexate Oral Formulation: Enhanced Aqueous Solubility, Bioavailability, Photostability, and Permeability

Pharmaceutics, 2022
The poor aqueous solubility and/or permeability and thereby limited bioavailability largely restricts the pharmaco-therapeutic implications of potent anticancer drugs such as methotrexate (MTX).
Bhupendra Raj Giri, Hyun Seok Yang, Im-Sook Song, Han-Gon Choi, Jung Hyun Cho, Dong Wuk Kim   +5 more
doaj   +1 more source

Enhancing Dissolution and Oral Bioavailability of Ursodeoxycholic Acid with a Spray-Dried pH-Modified Extended Release Formulation

Pharmaceutics, 2022
Ursodeoxycholate (UDCA) has low oral bioavailability and pH-dependent solubility and permeability. Thus, we developed a pH-modified extended-release formulation of UDCA using Na2CO3 as the alkalizing agent and hydroxypropyl methylcellulose (HPMC) as the ...
Jaehyeok Lee, Chul Haeng Lee, Jong-Geon Lee, So Yeon Jeon, Min-Koo Choi, Im-Sook Song   +5 more
doaj   +1 more source

Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting

Pharmaceuticals, 2023
Doxorubicin (DOX), a widely used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations that induce apoptosis, topoisomerase II inhibition, and histone ...
Jihoon Lee, Min-Koo Choi, Im-Sook Song
doaj   +1 more source

Improving Drug–Drug Interaction Extraction with Gaussian Noise

Pharmaceutics, 2023
Drug–Drug Interactions (DDIs) produce essential and valuable insights for healthcare professionals, since they provide data on the impact of concurrent administration of medications to patients during therapy.
Marco Molina, Cristina Jiménez, Carlos Montenegro   +2 more
doaj   +1 more source

Digoxin + Cyclosporine - contextualized potential drug-drug interaction clinical algorithm

, 2020
An algorithm developed for research purposes that summarizes the potential drug-drug interaction between digoxin and cyclosporine. The information is not advice, and should not be treated as such.
Contributors to the A Minimum Representation of Potential Drug-Drug Interaction Knowledge and Evidence - Technical and User-centered Foundation Specification
core   +1 more source

Drug-drug interaction-related uncontrolled glycemia

Journal of Pharmacy and Bioallied Sciences, 2017
Context: The literature of drug-drug interaction (DDI)-related uncontrolled causality, and preventability of DDI-induced UCG (HbA1c >7%) in outpatients glycemia (UCG) among outpatients with Type 2 diabetes mellitus is still limited. Aims: The aim of this
Mohamed Anwar Hammad, Balamurugan Tangiisuran, Abeer Mohamed Kharshid, Noorizan Abdul-Aziz, Yahaya Hassan, Nor Azizah Aziz, Tarek Mohamed Elsayed   +6 more
doaj   +1 more source

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications

Current Therapeutic Research
Objective: This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.
Jingjing Yu, MD, PhD, Sophie Argon, PharmD, Katie Owens, BPharm, PhD, Yan Wang, MS, Isabelle Ragueneau-Majlessi, MD, MS   +4 more
doaj   +1 more source

Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants

Pharmaceutics, 2022
Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lacking.
Rakshit S. Tanna, James T. Nguyen, Deena L. Hadi, Preston K. Manwill, Laura Flores-Bocanegra, Matthew E. Layton, John R. White, Nadja B. Cech, Nicholas H. Oberlies, Allan E. Rettie, Kenneth E. Thummel, Mary F. Paine   +11 more
doaj   +1 more source